CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) (USD $)	3 Months Ended
	Mar. 31, 2015	Mar. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss attributable to BioTime, Inc.	$ (10,167,368)	$ (8,099,014)
Net loss attributable to non-controlling interest	(2,422,687)	(1,629,017)
Adjustments to reconcile net loss attributable to BioTime, Inc. to net cash used in operating activities:
Depreciation expense	262,600	256,945
Amortization of intangible assets	1,314,094	1,367,998
Amortization of deferred consulting fees	0	16,279
Amortization of deferred license fees	27,375	27,375
Amortization of deferred license, royalty and subscription revenues	0	(280)
Amortization of prepaid rent in common stock	21,146	21,146
Stock-based compensation	1,914,407	801,554
Amortization of discount on related party convertible debt	49,697	0
Accrued interest on convertible debt	3,531	0
Loss on sale or write-off of equipment	0	8,576
Deferred income tax benefit	(1,176,882)	(1,349,026)
Deferred grant income	1,474,300	0
Changes in operating assets and liabilities:
Accounts receivable, net	(56,598)	(24,441)
Grant receivable	228,191	202,122
Inventory	(33,286)	(57,894)
Prepaid expenses and other current assets	(60,769)	(375,224)
Accounts payable and accrued liabilities	(365,175)	(1,276,211)
Other long term liabilities	10,727	(185,717)
Deferred rent liabilities	(62,313)	(5,040)
Deferred revenues	(29,811)	(57,402)
Net cash used in operating activities	(9,068,821)	(10,357,271)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of equipment	(77,007)	(231,921)
Payments on construction in progress (see Note 4)	(296,382)	0
Proceeds from the sale of equipment	0	4,000
Security deposit paid, net	0	(299,697)
Cash used in investing activities	(373,389)	(527,618)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from exercises of stock options	346,713	58,500
Proceeds from sale of preferred stock	0	3,500,000
Proceeds from issuance of common shares	0	8,182,559
Fees paid on sale of common stock	0	(212,046)
Proceeds from sale of treasury stock and subsidiary warrants	0	599,472
Reimbursement from landlord on construction in progress (see Note 4)	283,764	0
Repayment of capital lease obligation	(13,983)	0
Proceeds from sale of common shares of subsidiary	5,499,995	0
Fees paid on sale of common shares of subsidiary	(432,631)	0
Net cash provided by financing activities	5,683,858	12,128,485
Effect of exchange rate changes on cash and cash equivalents	100,976	(101,240)
NET CHANGE IN CASH AND CASH EQUIVALENTS:	(3,657,376)	1,142,356
CASH AND CASH EQUIVALENTS:
At beginning of the period	29,486,909	5,495,478
At end of the period	$ 25,829,533	$ 6,637,834